Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.

Kr├╝ger M, Beger C, Welch PJ, Barber JR, Manns MP, Wong-Staal F.

Mol Cell Biol. 2001 Dec;21(24):8357-64.

2.

Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis.

Das S, Ott M, Yamane A, Venkatesan A, Gupta S, Dasgupta A.

Front Biosci. 1998 Dec 1;3:D1241-52. Review.

PMID:
9835647
3.

Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses.

Dasgupta A, Das S, Izumi R, Venkatesan A, Barat B.

FEMS Microbiol Lett. 2004 May 15;234(2):189-99. Review.

4.

Hepatitis C IRES: translating translation into a therapeutic target.

Jubin R.

Curr Opin Mol Ther. 2001 Jun;3(3):278-87. Review.

PMID:
11497352
5.

Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets.

Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, Rice CM.

Antivir Ther. 1998;3(Suppl 3):71-81. Review.

PMID:
10726057
6.

Mechanism of translation initiation on hepatitis C virus RNA.

Nomoto A, Tsukiyama-Kohara K, Kohara M.

Princess Takamatsu Symp. 1995;25:111-9. Review.

PMID:
8875615
7.

Hepatitis C viral protein translation: mechanisms and implications in developing antivirals.

Hoffman B, Liu Q.

Liver Int. 2011 Nov;31(10):1449-67. doi: 10.1111/j.1478-3231.2011.02543.x. Epub 2011 May 5. Review.

PMID:
21745290
8.

Oligonucleotide-based strategies to inhibit human hepatitis C virus.

Martinand-Mari C, Lebleu B, Robbins I.

Oligonucleotides. 2003;13(6):539-48. Review.

PMID:
15025918
9.

Translation of hepatitis C virus genome.

Ali N, Wang C, Siddiqui A.

Princess Takamatsu Symp. 1995;25:99-110. Review.

PMID:
8875614
10.

Therapeutic targeting of HCV internal ribosomal entry site RNA.

Davis DR, Seth PP.

Antivir Chem Chemother. 2011;21(3):117-28. doi: 10.3851/IMP1693. Review.

PMID:
21233533
11.

Proteasome (prosome) associated endonuclease activity.

Petit F, Jarrousse AS, Boissonnet G, Dadet MH, Buri J, Briand Y, Schmid HP.

Mol Biol Rep. 1997 Mar;24(1-2):113-7. Review.

PMID:
9228291
12.

Therapeutic applications of ribozymes.

Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ.

Pharmacol Ther. 1995;68(2):247-67. Review.

PMID:
8719970
13.

Relationships between proteasomes and RNA.

Schmid HP, Pouch MN, Petit F, Dadet MH, Badaoui S, Boissonnet G, Buri J, Norris V, Briand Y.

Mol Biol Rep. 1995;21(1):43-7. Review.

PMID:
7565663
14.

[Reversal of drug resistance in human cancer cells by anti-oncogenes].

Funato T.

Gan To Kagaku Ryoho. 1997 Feb;24(4):395-400. Review. Japanese.

PMID:
9063474
15.

Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C.

Caselmann WH, Eisenhardt S, Alt M.

Intervirology. 1997;40(5-6):394-9. Review.

PMID:
9675643
16.

Recent advances in prevention and treatment of hepatitis C virus infections.

Wang QM, Heinz BA.

Prog Drug Res. 2001;Spec No:79-110. Review.

PMID:
11548211
17.

Recent advances in prevention and treatment of hepatitis C virus infections.

Wang QM, Heinz BA.

Prog Drug Res. 2000;55:1-32. Review.

PMID:
11127961
18.

Methods for studying IRES-mediated translation of positive-strand RNA viruses.

Wang QS, Au HH, Jan E.

Methods. 2013 Feb;59(2):167-79. doi: 10.1016/j.ymeth.2012.09.004. Epub 2012 Sep 23. Review.

PMID:
23009811
19.

[Down-regulation of a gene-expression by an antisense BNA oligonucleotide].

Imanishi T, Obika S.

Nihon Yakurigaku Zasshi. 2002 Aug;120(2):85-90. Review. Japanese.

PMID:
12187626
20.

Ribozymes: structure, function, and potential therapy for dominant genetic disorders.

Grassi G, Marini JC.

Ann Med. 1996 Dec;28(6):499-510. Review.

PMID:
9017109

Supplemental Content

Support Center